Who are ketamine- dexmeditomidine admixure's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamine-dexmeditomidine-admixure.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ketamine- dexmeditomidine admixure — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ketamine- dexmeditomidine admixure (ketamine- dexmeditomidine admixure) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dissociative anesthetic with alpha-2 adrenergic agonist. Area: Anesthesia.

marketed Dissociative anesthetic with alpha-2 adrenergic agonist NMDA receptor (ketamine); alpha-2 adrenergic receptor (dexmedetomidine) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

ketamine- dexmeditomidine admixure (ketamine- dexmeditomidine admixure) — Kasr El Aini Hospital. This admixture combines ketamine (an NMDA receptor antagonist) with dexmedetomidine (an alpha-2 adrenergic agonist) to provide dissociative anesthesia with sedation and analgesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ketamine- dexmeditomidine admixure TARGET	ketamine- dexmeditomidine admixure	Kasr El Aini Hospital	marketed	Dissociative anesthetic with alpha-2 adrenergic agonist	NMDA receptor (ketamine); alpha-2 adrenergic receptor (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dissociative anesthetic with alpha-2 adrenergic agonist class)

Kasr El Aini Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ketamine- dexmeditomidine admixure — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-dexmeditomidine-admixure. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab